Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that it has entered into a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada, focused on accelerating the development of new treatments for neurodegenerative diseases.